Learn more about our ongoing INFRONT trial of AL001 for the treatment of frontotemporal dementia (FTD).
Learn more about our ongoing INVOKE trial of AL002 for the treatment of Alzheimer's disease.
Learn more about our ongoing INTERCEPT trial of AL003 for the treatment of Alzheimer's disease.
Frontotemporal dementia (FTD) is a form of dementia found most frequently in individuals less than 65 years old at time of diagnosis. FTD affects roughly 50,000 to 60,000 individuals in the United States and roughly 110,000 individuals in the European Union. FTD is a rapidly progressing degenerative syndrome characterized by prominent cognitive dysfunction, behavioral and personality changes, and language deficits. The average life expectancy in FTD patients is seven to 10 years after the onset of symptoms.
The Association for Frontotemporal Degeneration
Alzheimer’s disease is a degenerative brain disease and the most common form of dementia. It is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear in their mid-60s. Estimates vary, but experts suggest that more than 5.5 million Americans may have Alzheimer’s.
Alzheimer's Association for AD: